PSIL AdvisorShares Psychedelics ETF Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:46
Sep 07
Sep 07
The author uses PSIL as the primary benchmark for the psychedelic sector, which they named their 'Best Idea' for 2026, arguing that despite recent outperformance, 'the broader story may still be in it
The author uses PSIL as the primary benchmark for the psychedelic sector, which they named their 'Best Idea' for 2026, arguing that despite recent outperformance, 'the broader story may still be in its early innings.'
Risk: Sector is highly dependent on FDA approvals, trial designs, and overcoming the difficulty of conducting blinded psychedelic studies.
19:40
Aug 25
Aug 25
Tiny PSIL ETF signals early psychedelics upside.
Author says PSIL is the only small psychedelics ETF and that the space is early, but does not state ownership, a buy/hold action, or a clear forward trade call.
MED
19:30
Aug 25
Aug 25
Author is bullish on psychedelics and explicitly hopes CMPS catches up.
Author is bullish on psychedelics and explicitly hopes CMPS catches up, implying a forward-looking long view while PSIL is context.
LOW
14:00
Jul 23
Jul 23
Psychedelic stocks poised for asymmetric gains.
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
HIGH
23:06
Jul 15
Jul 15
Author recommends PSIL as a diversified vehicle to capture the anticipated M&A wave and institutional acceptance of psychedelic therapies, with a long-term price target above $100.
HIGH
13:50
Jul 05
Jul 05
Author references PSIL's 35% YTD gain and maintains a long-term favorable view on the psychedelics sector, which the ETF tracks.
Author references PSIL's 35% YTD gain and maintains a long-term favorable view on the psychedelics sector, which the ETF tracks.
Risk: Sector concentration; regulatory and sentiment shifts could lead to sharp drawdowns.
17:45
Apr 22
Apr 22
Psychedelics have high clinical success rates.
Psychedelics are becoming medically accepted again with clinical trials showing up to 80% responder rates for treatment-resistant depression, addiction, and anxiety disorders. The recent executive order from President Trump accelerates federal funding for research, and the drugs are used in a clinical setting with a therapist, ensuring safety and efficacy. The sector has strong growth potential and companies have patent protection and intellectual property.
HIGH
18:57
Apr 20
Apr 20
PSIL ETF responsive to regulatory catalysts.
The PSIL (psychedelics) ETF, which had been depressed, saw a significant price pop and high trading volume after positive regulatory news (an executive order expediting research), suggesting that any good news can lead to substantial upside in such beaten-down, headline-sensitive thematic ETFs.
MED
14:09
Apr 20
Apr 20
Reports volume record and executive order catalyst for psychedelics sector.
Reports volume record and executive order catalyst for psychedelics sector; no personal directional commitment, only observation.
MED
About PSIL Analyst Coverage
Buzzberg tracks PSIL (AdvisorShares Psychedelics ETF) across 6 sources. 3 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (33%). 9 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Quoth the Raven, incomesharks, Chris Irons.